Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conditioning with Fludarabine, Busulfan, and Thymoglobulin for PBSC Transplant
NCT01056614Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Sep 2004
- Primary completion
- Aug 2005
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan, fludarabine and antithymocyte globulin rabbit in acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and 1 more, sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Incidence of acute Graft-versus-Host Disease at Day 100. Started Sep 2004; status: completed.
02
Drugs
busulfanfludarabineantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)chronic myelogenous leukemia (CML)myelodysplastic syndrome (MDS)myeloproliferative neoplasms (MPN)
Beyond the preview
Go deeper on NCT01056614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01056614.